Economics Of Gaining Approval For Unapproved Phenylephrine Remains Question Mark
Executive Summary
West-Ward could be the first to gain approval for phenylephrine in hypotension, but the drug’s widespread use as a stand-by medication during surgery could deter FDA enforcement against unapproved versions.
You may also be interested in...
Endpoint Selection Still An Issue For Publication-Based NDAs
FDA’s Cardiovascular and Renal Drugs Advisory Committee Sept. 13 indicated approval for currently marketed phenylephrine to treat hypotension in the peri-operative setting based on the ability to increase blood pressure, but voted 8-2 against its use in shock because of the need for outcomes data.
Makena’s Orphan Exclusivity Is “Nullified” By FDA’s Compounding Policy, KV Suit Says
KV seeks a court order requiring FDA to desist from permitting importation of unapproved API for compounded hydroxyprogesterone and to state its intent to take enforcement action against compounders.
Importation Should Be Preemptive Tool During Shortages, Group Tells FDA
The Greater New York Hospital Association, in a meeting with FDA Commissioner Margaret Hamburg, says the agency should be more proactive when considering importation of unapproved drugs to mitigate a shortage.